Swedish Orphan Biovitrum (BIOVF)
(Delayed Data from OTC)
$25.76 USD
0.00 (0.00%)
Updated May 3, 2024 09:52 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BIOVF 25.76 0.00(0.00%)
Will BIOVF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BIOVF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIOVF
All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy
Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates
BIOVF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?
Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates
Other News for BIOVF
Swedish Orphan Biovitrum assumed with a Buy at Jefferies
Apellis, Sobi present one-year data from Phase 2 study of pegcetacoplan
SEB Equities gets more bearish on Swedish Orphan Biovitrum, downgrades shares
Swedish Orphan Biovitrum AB reports Q1 results
Swedish Orphan Biovitrum AB (publ) 2024 Q1 - Results - Earnings Call Presentation